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Abstract
Objective: To identify and analyze the criteria, approaches, and conceptual frameworks, used for national/
international priority setting.
Data sources: We performed a search of the main biomedical databases (Medline/PubMed, Embase, Centre for
Reviews and Dissemination, and Cochrane), and we reviewed assessment agency websites, among other sources.
Study design: An systematic review of the literature was carried out.
Data collection: Eligibility criteria for inclusion were based on set of predefined criteria. Systematic reviews and/or
qualitative studies (interviews, surveys, expert consensus, etc) that aimed to identify prioritization criteria or develop
general operational frameworks for the selection of health priorities were included. A critical analysis is made of all
the aspects that may be useful for any public body that intends to establish priorities in health.
Principal findings: We found that there are no standardized criteria for priority setting, although common trends
have been identified regarding key elements. Eight key domains were identified: 1) need for intervention; 2) health
outcomes; 3) type of benefit of the intervention; 4) economic consequences; 5) existing knowledge on the
intervention/quality and uncertainties of the regarding evidence; 6) implementation and complexity of the
intervention/feasibility; 7) justice and ethics; and 8) overall context.
Conclusions: Our review provides a thorough analysis of the relevant issues and offers key recommendations
regarding considerations for developing a national prioritization framework. Findings are envisioned to be useful for
different public organizations that are aiming to establish healthcare priorities.
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Introduction
A health technology is defined as an intervention that
may be used to promote health, to prevent, diagnose or
treat acute or chronic disease, or for rehabilitation.
Health technologies include pharmaceuticals, devices,
procedures and organizational systems used in health
care [1].
The World Health Organization (WHO) state that
defines health technology assessment (HTA) refers to
the systematic evaluation of properties, effects, and/or
impacts of health technology [2]. It is a multidisciplinary
process to evaluate the social, economic, organizational
and ethical issues of a health intervention or health
technology [3].
The main purpose of conducting our assessment is to
develop an explicit priority setting methodology to
support decision-making regarding Medicines and Med-
ical Devices to be included in Hospital Pharmacy prac-
tice. The development of a comprehensive prioritization
system is the outcome essential for an important benefit
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Table 1 Criteria for the selection of studies
Types of publications Inclusion: articles published in peer-reviewed journals and documents published on official websites
Exclusion: communications to congresses, letters to the editor, editorials, commentaries
Types of articles / documents Inclusion: original articles (qualitative studies, surveys, interviews, consensus methods, panels of experts), systematic
reviews, formulations of conceptual frameworks based on evidence / expert opinion, guidelines / procedures manuals
or dissemination articles
Exclusion: opinion articles
Scope Inclusion: articles that address the identification, selection or categorization of prioritization criteria, define or propose
strategic or operational frameworks for the selection of health priorities, or describe the mechanisms or processes
employed by different national and international agencies to prioritize medicinal products and medical devices
Exclusion: methodological developments
Area Inclusion: prioritization processes designed to inform reimbursement and financing policies
Exclusion: prioritization processes aimed at other areas (inform the development of guidelines, clinical protocols,
detection systems of new or emerging technologies, observation of technologies, disinvestment, health technology
assessment units, etc.)
Language Inclusion: English. Also, Spanish, Italian, French and Portuguese.
Time frame Unlimited
Fig. 1 PRISMA 2009 Flow Diagram
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Table 2 Priority setting criteria. Main sources
Domain Considered criteria Alternative categorizations /
subgroupings
Need for intervention -Severity of the disease / condition Target disease
- Population size - Severity of the disease
-Unmet need / availability of alternatives -Determinants of the disease
-Burden of illness / threat to life
-Economic burden of the disease
-Epidemiology
Therapeutic context
-Therapeutic alternatives / need not met
-Need
-Clinical practice guidelines and protocols
-Existing use
Health results -Benefits in health / clinical Clinical benefits
-Efficacy / Effectiveness - General clinical benefits
- Safety / tolerability -Effect on mortality
-Health perceived by the patient -Effect on longevity
-Quality of care -Effect on quality of life
Health perceived by the patient:
-Quality of life
- Autonomy
- Impact on dignity
- Improved use / administration
Adequacy
- Efficiency and safety
- Effectiveness
Response level
- Quality of care received by the patient
- Burden of disease
Type of benefit of the intervention -Preventive benefits
-Therapeutic benefits
Economic consequences / economic
impact
-Costs of the intervention Efficiency
- Medical / health costs - Cost effectiveness / benefit
- Non-medical costs (productivity, cost, patients,
caregivers)
- Budget impact
-Impoverishment for the patient - Costs
- Budget impact Financing
-Financial impact - Unit cost
-Impact on productivity - Budget impact
-Impact on other services - Financing agent
-Efficiency and opportunity cost Cost of opportunity and affordability (context-
dependent criteria)
-Cost-effectiveness - Opportunity cost and if the system can
afford it
Existing knowledge about the intervention /
Quality and uncertainty of the evidence
-Evidence available Other considerations
-Quality of the evidence Quality of clinical and economic evidence
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Table 2 Priority setting criteria. Main sources (Continued)
Domain Considered criteria Alternative categorizations /
subgroupings
-Relevance of the evidence Consistency with strategic aspects
-Uncertainty of the evidence
-Expert consensus / clinical practice guidelines
Implementation and complexity of
the intervention / Feasibility
-Regulatory requirements / legislation
-Organizational requirements
-Technological requirements
-Requirements of personnel
-Training / personal skills requirements
-Information requirements
-Implementation flexibility
-Features of the intervention
-Appropriate use
-Barriers and acceptability
-Integration and efficiency of the system
-Sustainability
-Accessibility to the population
Ethics and justice -Population priorities Priority, ethics and justice
-Access - Low socioeconomic status
-Vulnerability - Children (0–5 years old or elderly)
-Utility - Subjects of productive age
-Solidarity - Women in productive age
-Ethics and moral aspects - Remote communities
- Therapeutic specific areas
- Response behavior
- Rare diseases
- Specific groups of patients
Equity
- General
- Accessibility
- Accessibility for the individual
Other ethical and social values
- Autonomy
- Value public health
- Impact in future generations
- Risk social and financial
- Catastrophic sanitary cost
- Economic productivity and care for
third parties
- Rare diseases-Population priorities
Global context -Mandate and mission of the health system Governance / leadership
-Alignment with regulations and strategies - Congruence with prior prioritization
- Global priorities / alignment with priority lines
(vulnerable groups, disabled, diseases, rare, etc.)
- Cultural acceptability
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to the healthcare system [4]. The aim of this research is
to identify and analyze the processes and decision cri-
teria used internationally for priority setting in order to
establish a comprehensive set of strategic criteria for
starting point for the development of a Medicines and
Medical Devices prioritization framework.
Methods
A systematic search of the literature was carried out in
December 2017, in the main biomedical electronic data-
bases: Medline/PubMed, Embase, Centre for Reviews and
Dissemination (CRD), and Cochrane. For this, a specific
search strategy was designed combining the terms: “medi-
cine”, “technology assessment, biomedical”, “technology”,
“intervention” with “priority”, “prioriti*”, “selection” with
“criteria”, “Setting”, “approach*”and “procedure*”. The de-
tailed search terms for different electronic databases is
listed in Additional file 1. Eligibility criteria for inclusion /
exclusion were based on set of predefined criteria
(Table 1). Systematic reviews and/or qualitative studies
(interviews, surveys, expert consensus, etc) that aimed to
identify prioritization criteria or develop general oper-
ational frameworks for the selection of health priorities
were included. The web pages of the international agen-
cies belonging to EUnetHTA and INAHTA were
reviewed, and manually searched in the main scientific
journal of the specialty (International Journal of Technol-
ogy Assessment Health Care) [5–8]. In addition, a general
search was carried out in the Google and Google Scholar
search engine to locate gray literature, and bibliographic
citations of included studies were reviewed. For perusal of
the complete text, we selected records in which any type
of pharmaceutical or medical product was assessed. It was
not considered relevant to apply a methodological quality
scale or gradation of evidence when not addressing a clin-
ical research question. Data of the studies were analyzed
and synthesized qualitatively.
Results
A total of 17 documents complied with eligibility cri-
teria, out of which 15 were published in scientific jour-
nals [9–23] and two elsewere [24, 25]. Fig. 1 details the
selection process of the articles and the reasons for
exclusion of potentially relevant articles. The studies
showed great heterogeneity. A total of 56 potentially
relevant priority setting criteria were identified, which
could be grouped in eight categories: 1) Need for inter-
vention; 2) Outcomes of intervention; 3) Type of benefit;
4) Economic consequences; 5) Existing knowledge/qual-
ity of evidence and uncertainties; 6) Implementation
complexity/feasibility; 7) Justice and equity; and 8) Con-
text. Table 2 describes these eight categories. Table 2
describes the domains and general criteria identified or
proposed in these studies, detailing the conceptual terms
used to classify them.
The current work includes eight studies that address the
identification, selection or classification of criteria used in
the international arena for the establishment of health
priorities. [10–16] Three of the studies retrieved refer to
the EVIDEM (Evidence and Value: Impact on Decision
Making) tool. In this multicriteria tool, developed from a
thorough analysis of the literature, the opinion of experts
and different international experiences, refers to 13 uni-
versal quantitative criteria (5 domains) and 7 contextual
qualitative criteria (3 domains). [10–12]
Discussion
The results of our review show that, despite a general
agreement regarding the need to establish rational and
transparent procedures to prioritize medicinal products
and medical devices, and a certain concordance with
respect to critical domains exists, there is scarce infor-
mation available on the explicit processes employed by
the evaluation agencies for the establishment of priority
issues [26–29].
Table 2 Priority setting criteria. Main sources (Continued)
Domain Considered criteria Alternative categorizations /
subgroupings
-Financial Restriction - Political acceptability
-Incentives - Acceptability of interest groups
-Political aspects - Legal Barriers
- Historical aspects
-Cultural aspects
-Degree of innovation
-Collaboration and leadership
-Implementation of patients
-Pressure of different interest groups
-Environmental impact
Main references used: EVIDEM tool [10, 11] and Guindo [13], Golan [14], Tanios [15], Tromp [16] studies
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This review can be used by different bodies interested
in priorization framework. All domains and criteria have
advantages and limitations, despite the fact all themes
were devised rigorously. It should be noted that the
present review is limited by the difficulties inherent in
the bibliographic search. To improve efficiency, the
search has been restricted to the title, so it is possible to
have lost some relevant article despite using different
combinations of keywords and related terms. In
addition, in many cases this type of information is not
published in scientific journals and is difficult to recover
due to the serious shortcomings of the search engines of
web pages, or because it is published in other languages.
In any case, we believe that this would not detract from
the current work, since we do not intend to describe all
international experiences, but to identify those criteria
and elements that may be key to the development of a
national prioritization proposal. The implementation sci-
ence principles for pharmacist and other healthcare pro-
viders, discovering and applying strategies designed to
incorporate evidence-based interventions into routine
practice is a must [30].
Conclusion
Our review provides a thorough analysis of the relevant
issues and offers key recommendations regarding
considerations for developing a national prioritization
framework. Findings are envisioned to be useful for dif-
ferent public organizations that are aiming to establish
healthcare priorities.
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